Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease

Rheumatic Disease Clinics of North America

Volumn 40, Issue 4, 2014, Pages 797-811

  Simmons, Kimber ^a   Michels, Aaron W ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Autoantibodies; Autoimmunity; Immune therapies; Prevention; Type 1 diabetes

Indexed keywords

ABATACEPT; AUTOANTIBODY; AZATHIOPRINE; BIOLOGICAL PRODUCT; HYDROXYCHLOROQUINE; INSULIN; INSULIN ZINC SUSPENSION; LEFLUNOMIDE; METHOTREXATE; NICOTINAMIDE; PLACEBO; SALAZOSULFAPYRIDINE; TEPLIZUMAB; ANTIBODY CONJUGATE; ANTIDIABETIC AGENT; HLA D ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; VITAMIN B COMPLEX;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONTINUOUS INFUSION; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEREDITY; HISTORY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; MORBIDITY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYDIPSIA; POLYURIA; PRIMARY PREVENTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SECONDARY PREVENTION; WEIGHT REDUCTION; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; DIET THERAPY; DISEASE COURSE; EARLY INTERVENTION; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PANCREAS ISLET; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ABATACEPT; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; DIET THERAPY; DISEASE PROGRESSION; EARLY MEDICAL INTERVENTION; GENETIC PREDISPOSITION TO DISEASE; HLA-D ANTIGENS; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS; NIACINAMIDE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SECONDARY PREVENTION; VITAMIN B COMPLEX;

EID: 84908066897     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.07.008     Document Type: Review

References (75)

1. Atkinson M.A., Eisenbarth G.S., Michels A.W. Type 1 diabetes. The Lancet 2014, 383(9911):69-82.
2. Karvonen M., Viik-Kajander M., Moltchanova E., et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000, 23(10):1516-1526.
3. Haller M.J., Atkinson M.A., Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am 2005, 52(6):1553-1578.
4. Rewers M., Bugawan T.L., Norris J.M., et al. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia 1996, 39(7):807-812.
5. Levy-Marchal C., Patterson C.C., Green A., EURODIAB ACE Study Group.Europe and Diabetes, et al. Geographical variation of presentation at diagnosis of type I diabetes in children: the EURODIAB study. European and Diabetes. Diabetologia 2001, 44(Suppl 3):B75-B80.
6. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. NEngl J Med 1986, 314(21):1360-1368.
7. Group DP Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med 2006, 23(8):857-866.
8. Harjutsalo V., Sjoberg L., Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008, 371(9626):1777-1782.
9. Patterson C.C., Dahlquist G.G., Gyurus E., et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009, 373(9680):2027-2033.
10. SEARCH for Diabetes in Youth Study Group, Liese A.D., D'Agostino R.B., Hamman R.F., et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006, 118(4):1510-1518.
11. Hamalainen A.M., Knip M. Autoimmunity and familial risk of type 1 diabetes. Curr Diab Rep 2002, 2(4):347-353.
12. Redondo M.J., Eisenbarth G.S. Genetic control of autoimmunity in Type I diabetes and associated disorders. Diabetologia 2002, 45(5):605-622.
13. Redondo M.J., Jeffrey J., Fain P.R., et al. Concordance for islet autoimmunity among monozygotic twins. NEngl J Med 2008, 359(26):2849-2850.
14. Barrett J.C., Clayton D.G., Concannon P., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009, 41(6):703-707.
15. Noble J.A., Valdes A.M., Cook M., et al. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996, 59(5):1134-1148.
16. Erlich H., Valdes A.M., Noble J., et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008, 57(4):1084-1092.
17. Polychronakos C., Li Q. Understanding type 1 diabetes through genetics: advances and prospects. Nat Rev Genet 2011, 12(11):781-792.
18. Pugliese A., Zeller M., Fernandez A., et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997, 15(3):293-297.
19. Lee Y.H., Bae S.C., Choi S.J., et al. The association between the PTPN22 C1858T polymorphism and rheumatoid arthritis: a meta-analysis update. Mol Biol Rep 2012, 39(4):3453-3460.
20. Stene L.C., Oikarinen S., Hyoty H., et al. Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 2010, 59(12):3174-3180.
21. Hypponen E., Laara E., Reunanen A., et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358(9292):1500-1503.
22. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008, 93(6):512-517.
23. Snell-Bergeon J.K., Smith J., Dong F., et al. Early childhood infections and the risk of islet autoimmunity: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetes Care 2012, 35(12):2553-2558.
24. Hummel S., Pfluger M., Hummel M., et al. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 2011, 34(6):1301-1305.
25. Watkins R.A., Evans-Molina C., Blum J.S., et al. Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. Transl Res 2014, 164(2):110-121.
26. Steck A.K., Johnson K., Barriga K.J., et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care 2011, 34(6):1397-1399.
27. Ziegler A.G., Rewers M., Simell O., et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013, 309(23):2473-2479.
28. Bingley P.J. Clinical applications of diabetes antibody testing. JClin Endocrinol Metab 2010, 95(1):25-33.
29. Padgett L.E., Broniowska K.A., Hansen P.A., et al. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci 2013, 1281:16-35.
30. Pugliese A., Yang M., Kusmarteva I., et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes 2014, 15(1):1-9.
31. Spencer J., Peakman M. Post-mortem analysis of islet pathology in type 1 diabetes illuminates the life and death of the beta cell. Clin Exp Immunol 2009, 155(2):125-127.
32. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
33. Sosenko J.M., Skyler J.S., Krischer J.P., et al. Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes 2010, 59(10):2386-2389.
34. Ferrannini E., Mari A., Nofrate V., et al. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010, 59(3):679-685.
35. Orchard T.J., Costacou T., Kretowski A., et al. Type 1 diabetes and coronary artery disease. Diabetes Care 2006, 29(11):2528-2538.
36. Norgaard K. Anationwide study of continuous subcutaneous insulin infusion (CSII) in Denmark. Diabet Med 2003, 20(4):307-311.
37. Pickup J., Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002, 25(3):593-598.
38. Bode B.W., Steed R.D., Davidson P.C. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996, 19(4):324-327.
39. Boland E.A., Grey M., Oesterle A., et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999, 22(11):1779-1784.
40. Peyser T., Dassau E., Breton M., et al. The artificial pancreas: current status and future prospects in the management of diabetes. Ann N Y Acad Sci 2014, 1311(1):102-123.
41. Akerblom H.K., Virtanen S.M., Ilonen J., et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia 2005, 48(5):829-837.
42. Knip M., Virtanen S.M., Seppa K., et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. NEngl J Med 2010, 363(20):1900-1908.
43. Vaarala O., Ilonen J., Ruohtula T., et al. Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA Pilot Study. Arch Pediatr Adolesc Med 2012, 166(7):608-614.
44. Norris J.M., Yin X., Lamb M.M., et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007, 298(12):1420-1428.
45. Skyler J.S., Greenbaum C.J., Lachin J.M., et al. Type 1 Diabetes TrialNet-an international collaborative clinical trials network. Ann N Y Acad Sci 2008, 1150:14-24.
46. Michels A.W., von Herrath M. 2011 Update: antigen-specific therapy in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2011, 18(4):235-240.
47. Diabetes Prevention Trial-Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. NEngl J Med 2002, 346(22):1685-1691.
48. Skyler J.S., Krischer J.P., Wolfsdorf J., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005, 28(5):1068-1076.
49. Vehik K., Cuthbertson D., Ruhlig H., et al. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care 2011, 34(7):1585-1590.
50. Vandemeulebroucke E., Gorus F.K., Decochez K., et al. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab 2009, 35(4):319-327.
51. Martinez N.R., Augstein P., Moustakas A.K., et al. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. JClin Invest 2003, 111(9):1365-1371.
52. Harrison L.C., Honeyman M.C., Steele C.E., et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27(10):2348-2355.
53. Nanto-Salonen K., Kupila A., Simell S., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372(9651):1746-1755.
54. Dulin W.E., Wyse B.M. Reversal of streptozotocin diabetes with nicotinamide. Proc Soc Exp Biol Med 1969, 130(3):992-994.
55. Yamada K., Nonaka K., Hanafusa T., et al. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. An observation in nonobese diabetic (NOD) mice. Diabetes 1982, 31(9):749-753.
56. Lazarow A. Protection against alloxan diabetes. Anat Rec 1947, 97(3):353.
57. Herskowitz R.D., Jackson R.A., Soeldner J.S., et al. Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide. JAutoimmun 1989, 2(5):733-737.
58. Elliott R.B., Chase H.P. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991, 34(5):362-365.
59. Manna R., Migliore A., Martin L.S., et al. Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Br J Clin Pract 1992, 46(3):177-179.
60. Elliott R.B., Pilcher C.C., Stewart A., et al. The use of nicotinamide in the prevention of type 1 diabetes. Ann N Y Acad Sci 1993, 696:333-341.
61. Gale E.A., Bingley P.J., Emmett C.L., European Nicotinamide Diabetes Intervention Trial Group, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363(9413):925-931.
62. Lampeter E.F., Scherbaum W.A., Henize E., et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes Care 1998, 47:980-984.
63. Bohmer K.P., Kolb H., Kuglin B., et al. Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen. Diabetes Care 1994, 17(2):138-141.
64. Carel J.C., Boltard C., Eisenbarth G., et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. JAutoimmun 1996, 9:739-745.
65. Huppmann M., Baumgarten A., Ziegler A.G., et al. Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care 2005, 28(5):1204-1206.
66. Ziegler A.G., Schmid S., Huber D., et al. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003, 290(13):1721-1728.
67. Deane K.D., El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol 2014, 10(4):212-228.
68. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. NEngl J Med 2003, 349(16):1526-1533.
69. Demoruelle M.K., Parish M.C., Derber L.A., et al. Performance of anti-cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum 2013, 65(9):2243-2252.
70. Young K.A., Deane K.D., Derber L.A., et al. Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arthritis Rheum 2013, 65(8):1995-2004.
71. Majka D.S., Deane K.D., Parrish L.A., et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008, 67(6):801-807.
72. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376(9746):1094-1108.
73. Kolfenbach J.R., Deane K.D., Derber L.A., et al. Aprospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum 2009, 61(12):1735-1742.
74. O'Dell J.R., Mikuls T.R., Taylor T.H., et al. Therapies for active rheumatoid arthritis after methotrexate failure. NEngl J Med 2013, 369(4):307-318.
75. Smolen J.S., Aletaha D., Koeller M., et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370(9602):1861-1874.